Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

2014 Archived Content

Cambridge Healthtech Institute’s Eleventh Annual

Molecular Diagnostics

Executive Strategies for Success

The Industry Leader’s Networking Event

February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA


Medical practice is becoming dependent on molecular tests for therapy selection and treatment decisions, forcing a paradigm shift to enable personalized medicine. This reality will translate to great improvements in the speed, efficiency, accuracy and overall cost of medicine and allow for accountable care organizations (ACO). Cambridge Healthtech Institute's Molecular Diagnostics is known for bringing together industry leaders and providing a platform for major announcements. This year's meeting will address tactical challenges in the process of implementing personalized medicine throughout an organization and personalizing patient care including: how to pay for it, how to translate the results of tests to physicians and patients, and how to integrate it throughout an organization. Setting up systems for handling high volumes of multi-source data will be reviewed by key players in the industry. Practical guidelines for all aspects of personalized medicine and companion diagnostics will be considered and explored.

Scientific Advisory Board

Alan Carter, President, Complete Genomics
Dalia Cohen, Ph.D., Founder & President, ALN Associates
Harry Glorikian, Managing Partner, Strategy, Precision for Medicine 


Day 1 | Day 2 | Day 3 | Track Brochure | Full Event Brochure 

Monday, February 10

10:30 am Conference Program Registration

11:50 Chairperson’s Opening Remarks

Julien N. Bradley, MBA, Senior Director, Sales & Marketing, Quanterix Corporation




CPT Coding

Moderator: Jill Hagenkord, M.D., CMO & Senior Vice President, InVitae (2013 AMP Economic Affairs Committee and 2014 AMP Training and Education Committee)

Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP (2014 AMP President and 2013 AMP Economic Affairs, Professional Relations, Strategic Opportunities Committees)

Chris L. Jagmin, M.D., Senior Medical Director, National Medical Policy and Operations, Aetna

•          Overview of CPT codes
•          Transitioning to the molecular pathology codes from the clinical laboratory’s perspective
•          Understanding rationale behind new CPT codes

1:00 Session Break



1:15 Luncheon Presentation I: Simoa HD-1: A Fully Automated, Multiplexed Immunoanalyzer with Single Molecule Sensitivity

David C. Duffy, Ph.D., CTO, Quanterix Corporation

Single Molecule Array (Simoa) technology allows multiple proteins to be detected at concentrations 1000-fold lower than currently possible. Simoa is based on the capture of single molecules on paramagnetic beads, and their detection in arrays of femtoliter wells. We will illustrate the power of this analytical sensitivity in diagnosing cancer, neurological diseases, and infectious diseases using the Simoa HD-1 Analyzer, a fully automated instrument designed for use in clinical research and diagnosis.

1:45 Luncheon Presentation II: A Novel Exosome RNA Extraction Platform Enabling Biomarker Discovery and Diagnostic Development for Personalized Medicine

Johan Skog, Ph.D., CSO, Exosome Diagnostics

Exosomes are released by cells as an active process of communication, and contain stable, intact nucleic acids, making them an ideal source for biomarker discovery and diagnostic development. ExoRNeasy was optimized to extract RNA, including mRNA, microRNAs, and other RNAs, from plasma and serum. The high quality RNA generated from the ExoRNeasy kit enables profiling of tumor associated mutations as well as RNA levels in biofluids of cancer patients.

2:15 Session Break



2:30 PANEL DISCUSSION: Opportunities and Challenges in Commercializing Esoteric Diagnostics

Moderator: Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Organized by the Personalized Medicine Coalition, this panel will outline both the promise and the pitfalls in bringing new molecular diagnostics to market, including the scientific, regulatory, payment, and adoption issues that innovative diagnostics companies must negotiate. Featuring leaders in the field, it will provide insight into best practices and likely scenarios for future trends.

Peter Maag, Ph.D., CEO, XDx, Inc.

Jay Wohlgemuth, M.D., Senior Vice President, Science & Innovation, Quest Diagnostics

Alan Wright, M.D., MPH, CMO, Roche Diagnostics

Steven Rosenberg, Ph.D., CSO, CardioDx, Inc.



3:45 Next-Gen Sequencing for Prostate Cancer

Philip D. Cotter, Ph.D., FACMG, FFSc(RCPA), Principal, ResearchDx

Diagnostic and prognostic assessment of prostate cancer has been dramatically improved by the use of new laboratory technologies. This presentation focuses on the use of gene panel and pathway analyses using Next-Gen sequencing approaches in prostate cancer.



4:00 Models for the Development of Multiplex Companion Diagnostics 

Austin Tanney, Ph.D., Scientific Liaison Manager, Almac



4:15 A Bioinformatics Framework for Clinical Research Sequencing

Daniel Rhodes, Ph.D., Head, Medical Science Informatics, Life Technologies
The widespread adoption of precision medicine in oncology requires: a compendium of therapies targeting the genetic vulnerabilities of cancer; the diagnostic tools capable of generating a precise molecular diagnosis; and importantly, the information systems to connect a patient’s molecular diagnosis to optimal treatment hypotheses. Here, we will present Life Technologies’ work to accelerate (1) defining the landscape of actionable driver genetic events in cancer, (2) developing a next-generation sequencing screen on the Ion Torrent semiconductor-sequencing platform, (3) assembling treatment-related information relevant for clinical research, and (4) devising a turnkey bioinformatics solution to democratize clinical sequencing in the future. 


4:30 Refreshment Break and Transition to Plenary Keynote

5:00 Plenary Keynote Session (Click Here For More Details) 

6:15 Grand Opening Reception in the Exhibit Hall with Poster Viewing

7:45 Close of Day

Day 1 | Day 2 | Day 3 | Track Brochure | Full Event Brochure